CEOP-R regimen
|
WikiDoc Resources for CEOP-R regimen |
|
Articles |
|---|
|
Most recent articles on CEOP-R regimen Most cited articles on CEOP-R regimen |
|
Media |
|
Powerpoint slides on CEOP-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CEOP-R regimen at Clinical Trials.gov Trial results on CEOP-R regimen Clinical Trials on CEOP-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CEOP-R regimen NICE Guidance on CEOP-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CEOP-R regimen Discussion groups on CEOP-R regimen Patient Handouts on CEOP-R regimen Directions to Hospitals Treating CEOP-R regimen Risk calculators and risk factors for CEOP-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CEOP-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: R-CEOP; Rituximab/Cyclophosphamide/Epirubicin/Vincristine/Prednisone
Overview
CEOP-R regimen refers to an immunochemotherapy regimen consisting of cyclophosphamide, epirubicin, vincristine (Oncovin), prednisone and rituximab used to treat both indolent and aggressive forms of Diffuse large B-cell lymphoma.[1]
Regimen
CCyclophosphamide
EEpirubicin
OVincristine (Oncovin)
PPrednisone
RRituximab
Indications
References
- ↑ 1.0 1.1 Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L; et al. (2014). "Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression". Int J Hematol. 99 (1): 79–86. doi:10.1007/s12185-013-1472-z. PMID 24258714.